Emerging retatrutide, a dual -action treatment targeting equally GLP-1 and GIP receptors, is generating considerable excitement within the healthcare community. Initial clinical research have shown impressive losses in physical size and gains in physiological markers for people with excess weight . Scientists believe this unique approach may repres